Dasatinib Clinical Evidence for Aging: IPF, Frailty, and Alzheimer's
Expert Summary
Dasatinib + quercetin has progressed from preclinical discovery (2015) through multiple human trials (2018–2024) at remarkable speed. Across all trials, the consistent finding is measurable senescent cell burden reduction (via p16, SA-β-Gal, SASP factor biomarkers) and functional improvement proportional to the baseline disease severity.
Key Facts
- IPF pilot (Xu 2018, Nature Medicine): 9 patients. D+Q × 3 doses over 3 weeks. Adipose biopsy: -35% p16+p21+ cells. Physical function: gait speed, chair stands, stair climbing all improved. First published human senolytic trial.
- DKD trial (Hickson 2019, EBioMedicine): 9 patients with diabetic kidney disease. D+Q × 3 doses over 3 weeks. Reduction in p16, p21, macrophage marker CD68 in kidney biopsies. Circulating SASP factors (IL-6, MMP-3) reduced.
- Frailty trial (PMID: 31542391): Larger phase 2. 29 participants ≥70 years with physical frailty. D+Q vs placebo. Significant improvement in 400m gait speed (p=0.0001), 5x chair stands, SF-36 physical function. Strongest functional efficacy data to date.
- Alzheimer's trial (UT Health San Antonio): Pilot safety and pharmacodynamics in early Alzheimer's patients. D+Q reduced CSF p-tau-181 (a validated Alzheimer's biomarker) and SASP factors. No significant adverse events.
- Alzheimer's Phase 2 (ALSENLITE): Larger ongoing trial evaluating cognitive outcomes with D+Q in mild-to-moderate Alzheimer's. Recruitment completed; results pending.
- Safety across all trials: Thrombocytopenia (platelet reduction) is the most consistent side effect (observed in 2–3 of 9 patients in pilot studies) but is transient and resolves after treatment cessation. No severe adverse events attributed to D+Q in any published aging trial.
Recommended Products
Frequently Asked Questions
Which disease has the strongest D+Q evidence?
Physical frailty in older adults has the most statistically significant functional outcome data (gait speed improvement, p=0.0001). The IPF trial, while smaller, has the most direct cellular evidence (biopsy-confirmed senescent cell reduction).
Are the D+Q trial results generalizeable to healthy aging?
All trials enrolled patients with established disease. Extrapolation to healthy individuals suggests benefit (since senescent cells accumulate in all aging organisms) but direct RCT evidence in healthy elderly populations is still pending.
How long do D+Q benefits last after a single treatment cycle?
The frailty trial showed maintained improvements at 4 weeks post-treatment. Senescent cell reaccumulation data suggests benefits may persist 1–3 months before repeat treatment is needed for maintenance.
Scientific References
- Hickson LJ et al. Senolytics decrease senescent cells in humans. EBioMedicine. 2019. PMID: 31542391
- Justice JN et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human open-label pilot study. EBioMedicine. 2019. PMID: 30616998